AVCT — Avacta Share Price
Last trade - 00:00- £131.68m
- £129.61m
- £23.25m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.73 | ||
| Price to Tang. Book | 7.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.82 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -62.44% | ||
| Return on Equity | -73.02% | ||
| Operating Margin | -149.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 5.51 | 2.14 | 2.94 | 9.65 | 23.25 | 24.01 | 15.57 | 53.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Directors
- Eliot Forster NEC (55)
- Alastair Smith CEO
- Tony Gardiner CFO (49)
- Matt Vincent SVP
- Amrik Basran CSO
- Matt Johnson CSO
- Neil Bell OTH
- Mary Bronserud OTH
- David Wilson OTH
- Emma Wright OTH
- Mark Goldberg NED (67)
- Paul Fry NID
- Trevor Nicholls NID (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 29th, 2003
- Public Since
- September 8th, 2003
- No. of Employees
- 154
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 376,216,957
- Address
- Unit 20, Ash Way, WETHERBY, LS23 7FA
- Web
- https://avacta.com/
- Phone
- +44 1904217070
- Auditors
- BDO LLP
Latest News for AVCT
Upcoming Events for AVCT
Full Year 2024 Avacta Group PLC Earnings Release
Avacta Group PLC Annual Shareholders Meeting
Half Year 2025 Avacta Group PLC Earnings Release
Similar to AVCT
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 19:27 UTC, shares in Avacta are trading at 35.00p. This share price information is delayed by 15 minutes.
Shares in Avacta last closed at 35.00p and the price had moved by -29.65% over the past 365 days. In terms of relative price strength the Avacta share price has underperformed the FTSE All Share Index by -32.41% over the past year.
The overall consensus recommendation for Avacta is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAvacta does not currently pay a dividend.
Avacta does not currently pay a dividend.
Avacta does not currently pay a dividend.
To buy shares in Avacta you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 35.00p, shares in Avacta had a market capitalisation of £131.68m.
Here are the trading details for Avacta:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AVCT
Based on an overall assessment of its quality, value and momentum Avacta is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Avacta is 95.00p. That is 171.43% above the last closing price of 35.00p.
Analysts covering Avacta currently have a consensus Earnings Per Share (EPS) forecast of -£0.08 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avacta. Over the past six months, its share price has underperformed the FTSE All Share Index by -41.22%.
As of the last closing price of 35.00p, shares in Avacta were trading -34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Avacta PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 35.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Avacta's management team is headed by:
- Eliot Forster - NEC
- Alastair Smith - CEO
- Tony Gardiner - CFO
- Matt Vincent - SVP
- Amrik Basran - CSO
- Matt Johnson - CSO
- Neil Bell - OTH
- Mary Bronserud - OTH
- David Wilson - OTH
- Emma Wright - OTH
- Mark Goldberg - NED
- Paul Fry - NID
- Trevor Nicholls - NID